Recent Advances in Bipolar Depression - Roger McIntyre, MD
This activity has been designed to meet the educational needs of physicians, PCP’s, NP’s, PA’s, nurses involved in the care of patients with bipolar depression.
An efficacious long term therapy for bipolar depression remains one of the great unmet needs in the care of patients with bipolar disorder.
Clinicians need to consider not just the short term risk benefit ratio of the currently available efficacious treatments when choosing one for their patients but also long term adverse effects including weight gain, metabolic disturbances and cognitive effects. Of the three FDA approved treatments for bipolar depression there are differences in the side effect profiles which may affect clinician choice.
Estimated time to complete activity: 0.75 hours
Disclosure Of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to receive CME/CE credit for your participation in this activity, Please complete the online post-test, with a passing score of 70% or higher, and the online evaluation form; once completed, you will have immediate access to a certificate of attendance to print or save for your files.
There is no fee for this educational activity.
This activity is jointly sponsored/co-provided by Global Medical Education and Postgraduate Institute for Medicine.
This activity is supported by an educational grant from Sunovion Pharmaceuticals.
Accreditation:This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty Listing:Roger McIntyre, MD
Professor of Psychiatry
University of Toronto
- Discuss evidence based treatments both medications and psychotherapies for bipolar depression.
- Individualize treatment choices based on efficacy, safety and tolerability.
- Counsel the patients on strategies to improve outcomes in bipolar depression.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Roger McIntyre, MD: Advisory Boards : AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho, Eli Lilly, Organon , Lundbeck , Pfizer, Shire, Merck; Speakers Bureau : Janssen-Ortho, AstraZeneca, Eli Lilly, Lundbeck , Merck, Pfizer; Research Grants : Eli Lilly, Janssen-Ortho, Shire, AstraZeneca, Pfizer, Lundbeck
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following PIM planners and managers, Laura Excell , ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD , Samantha Mattiucci , PharmD , CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.